Jo1+, n = 13 | Jo1–, n = 78 | p | TIF1g+, n = 25 | TIF1g–, n = 66 | p | NXP2+, n = 17 | NXP2–, n = 74 | p | Mi2+, n = 12 | Mi2–, n = 79 | p | PM-Scl+, n = 9 | PM-Scl–, n = 82 | p | MDA5+, n = 5 | MDA5–, n = 86 | p | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Perifascicular atrophy | 62 | 49 | 0.6 | 64 | 45 | 0.2 | 53 | 50 | 1 | 67 | 48 | 0.4 | 33 | 52 | 0.3 | 40 | 51 | 0.7 |
Perivascular inflammation | 69 | 60 | 0.8 | 64 | 61 | 0.8 | 65 | 61 | 1 | 83 | 58 | 0.1 | 78 | 60 | 0.5 | 20 | 64 | 0.1 |
Primary inflammation | 31 | 22 | 0.5 | 12 | 27 | 0.2 | 0 | 28 | 0.01 | 50 | 19 | 0.03 | 67 | 18 | 0.004 | 0 | 24 | 0.6 |
Mitochondrial dysfunction | 25 | 29 | 1 | 47 | 18 | 0.05 | 25 | 29 | 1 | 29 | 28 | 1 | 0 | 30 | 0.6 | 50 | 27 | 0.5 |
Necrotizing myopathy | 15 | 17 | 1 | 8 | 20 | 0.2 | 18 | 16 | 1 | 8 | 18 | 0.7 | 22 | 16 | 0.6 | 0 | 17 | 0.6 |
Immunosuppressant prior to biopsy | 62 | 61 | 1 | 71 | 57 | 0.3 | 44 | 64 | 0.2 | 58 | 61 | 1 | 56 | 61 | 0.7 | 100 | 58 | 0.2 |
Immunosuppressant at biopsy | 55 | 55 | 1 | 51 | 67 | 0.2 | 44 | 58 | 0.4 | 50 | 56 | 0.8 | 44 | 56 | 0.5 | 100 | 53 | 0.1 |
Corticosteroids at biopsy | 31 | 49 | 0.4 | 58 | 42 | 0.2 | 38 | 48 | 0.6 | 50 | 45 | 1 | 33 | 48 | 0.5 | 80 | 44 | 0.2 |
Days from onset of symptoms to biopsy, median (Q1–Q3) | 721 (531–874) | 270 (114–497) | 0.02 | 270 (92–561) | 293 (128–721) | 0.5 | 125 (66–293) | 322 (153–777) | 0.01 | 163 (58–402) | 304 (128–663) | 0.1 | 232 (114–1880) | 293 (118–605) | 0.9 (296–637) | 403 (114–615) | 288 | 0.4 |
Deltoid biopsy | 36 | 42 | 1 | 60 | 34 | 0.06 | 20 | 45 | 0.2 | 29 | 43 | 0.7 | 14 | 44 | 0.2 | 50 | 41 | 1 |
Biceps biopsy | 9 | 7 | 1 | 0 | 10 | 0.3 | 20 | 5 | 0.1 | 0 | 8 | 1 | 0 | 8 | 1 | 0 | 8 | 1 |
Quadriceps biopsy | 55 | 51 | 1 | 40 | 56 | 0.3 | 60 | 50 | 0.7 | 71 | 49 | 0.4 | 86 | 48 | 0.1 | 50 | 51 | 1 |
Significant data indicated in bold face. TIF1-γ: transcriptional intermediary factor 1-γ.